Nodular Lymphocyte-Predominant B-cell Lymphoma (formerly NLPHL)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-NLPBL |
|---|---|
| Type | Disease |
| Aliases | Lymphocyte-predominant Hodgkin (legacy)NLPBLNLPHLNodular Lymphocyte-Predominant B-cell LymphomaНодулярна лімфоцит-домінантна B-клітинна лімфома (раніше NLPHL) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9659/3 |
|---|---|
| icd_10 | C81.0 |
| who_classification | Mature B-cell neoplasms — Nodular lymphocyte-predominant B-cell lymphoma per WHO 5th ed. (RECLASSIFIED from Hodgkin to B-cell in 5th ed.) |
Notes
WHO 5th-ed renamed NLPHL → NLPBL (now classified as B-cell, not Hodgkin). CD20+ → rituximab-responsive. Early-stage: ISRT alone curative in many. Advanced: R-CHOP-like (rituximab + chemo, reusing DLBCL pathway) preferred over ABVD.
Used By
Actionability
BMA-MYC-REARRANGEMENT-NLPBL- MYC rearrangement in nodular lymphocyte-predominant B-cell lymphoma is rare and typically...
Algorithms
ALGO-NLPBL-1L- ALGO-NLPBL-1LALGO-NLPBL-2L- ALGO-NLPBL-2L
Disease
DIS-CHL- Classical Hodgkin Lymphoma
Indication
IND-NLPBL-1L-OBSERVATION-OR-RT- IND-NLPBL-1L-OBSERVATION-OR-RTIND-NLPBL-1L-RITUXIMAB-MONO- IND-NLPBL-1L-RITUXIMAB-MONOIND-NLPBL-2L-RCHOP-TRANSFORMATION- IND-NLPBL-2L-RCHOP-TRANSFORMATION
Questionnaires
QUEST-NLPBL-1L-STUB- Nodular Lymphocyte-Predominant B-cell Lymphoma — first line
Red flag
RF-NLPBL-FRAILTY-AGE- Age >75 + ECOG ≥3 with asymptomatic stage I-II disease — observation alone is appropriate...RF-NLPBL-HIGH-RISK-BIOLOGY- Variant histology (T-cell rich, diffuse, or with histologic transformation to DLBCL/THRLB...RF-NLPBL-INFECTION-SCREENING- HBV/HCV/HIV serology pre-rituximab. NLPBL not associated with EBV (unlike classical Hodgk...RF-NLPBL-ORGAN-DYSFUNCTION- Pulmonary or cardiac dysfunction in field-of-RT region — radiation contraindicated; ritux...RF-NLPBL-RT-CONTRAINDICATED- Radiotherapy contraindicated or declined for early-stage NLPBL (nodular lymphocyte-predom...RF-NLPBL-TRANSFORMATION-PROGRESSION- Multiple relapses or histologic transformation to DLBCL/THRLBCL on rebiopsy — switch to a...
Sources
SRC-ESMO-HODGKIN-2024- ESMO Clinical Practice Guideline on Hodgkin Lymphoma